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Objective: In an attempt to find a better treatment for bacterial infections and burn
wounds,varioussemisolidformulationscontaining5%w/wofnorfloxacinwereprepared
and evaluated for physicochemical parameters, in vitro drug release through cellophane
membrane, antimicrobial activity, and burn wound healing properties. The prepared
formulationswerecomparedwithsilversulfadiazine1%cream,USP.Methods:Various
semisolid formulations were prepared with different bases like Carbopol, polyethylene
glycol,andhydroxypropylmethylcellulose,usingstandardprocedures.Theantimicrobial
activity of these semisolid norfloxacin formulations, against various strains of aerobic
and anaerobic microorganisms, was evaluated by using a standard cup-plate method.
The wound healing property was evaluated by measuring the wound contraction and
expressed as percentage of contraction of original wound size for each animal group.
Results: Antimicrobial activity of norfloxacin semisolid formulations was found to
be equally effective against both aerobic and anaerobic bacteria in comparison to a
formulation of silver sulfadiazine 1% cream, USP, available on the market. Conclusion:
The burn wound healing property of the prepared norfloxacin semisolid formulations
was found to be in good agreement with silver sulfadiazine 1% cream, USP, available
on the market.
Infection is a major complication of burn injury and is responsible for 50% to 75% of
hospital deaths. A moist, thermally coagulated burn wound, with its constantly replenished
supplyofdiffusingserumnutrientsandwarmsurfacetemperature,providesanenvironment
suitable for rapid microbial growth. As local microbial growth increases, the potential for
invasion to subjacent viable tissues and penetration into circulation increases.
Microorganisms that cause burn wound infections have changed over the years rel-
ative to changes in treatment. Ramakrishanan et al1 and Wang et al2 reported separately
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that anaerobic bacteria are the causative organisms for infection in around 15% of burn-
infected patients. Huo3 reported that silver norfloxacin proved valuable in the treatment of
burn wound infection caused by invading organisms, particularly by a silver sulfadiazine–
resistant strain of Pseudomonas.
Norfloxacin, a broad-spectrum fluoroquinolone antibacterial agent, is commonly em-
ployed in the treatment of urinary and genital tract infections.4−6 It is a hydrophilic fluoro-
quinolone with unique physiochemical properties such as low water solubility and partition
coefficient.7 The objective of the present study was to prepare various topical drug delivery
systemssuchasgelsandointmentsandevaluatetheirantimicrobialactivityandburnwound
healing efficacy and compare with silver sulfadiazine 1% cream, USP.
MATERIALS AND METHODS
Norfloxacin was obtained from Pfiscar India Ltd. (Murthal, Haryana, India) and Carbopol
from Noveon (Mumbai, India). All other chemicals used were of analytical grade. For
analysis, UV-spectrophotometer (Jasco V-530; Jasco Inc, Easton, MD) was used.
Preparation of transdermal formulations
Various semisolid formulations of norfloxacin were prepared, with different bases like Car-
bopol, polyethylene glycol, and hydroxypropylmethyl cellulose using standard procedures
(Table 1). In each of the formulations, norfloxacin was incorporated at 5% w/w concentra-
tion in the base with trituration using geometric dilution procedure to get a homogeneous
mass.
Table 1. Composition of various optimized dermatological bases containing 5% w/w norﬂoxacin
Dermatological base
Ingredients Carbopol, g HPMC, g∗ PEG, g Ointment, g
Norfloxacin 5.0 5.0 5.0 5.0
Carbopol gel base 95.0 ... ... ...
Propylene glycol ... ... ... ...
Methyl paraben ... 0.3 ... ...
Ethyl paraben ... 0.2 ... 10.0
HPMC gel base ... 2.0 ... ...
PEG 4000 ... ... 50.0 ...
PEG 300 ... ... 45.0 ...
DMSO ... ... ... 10.5 v/w
Isopropyl myristate ... ... ... 8.0 v/w
Mineral oil ... ... ... 30.0 v/w
White petrolatum ... ... ... 30.7 v/w
Bees wax ... ... ... 4.8 v/w
Glycerine ... 10.0 ... ...
Water ... q.s. ... 1.0 v/w
∗ HPMC indicates hydroxypropylmethyl cellulose; PEG, polyethylene glycol; DMSO, dimethyl sulfoxide; and q.s., quantity
sufficient.
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Table 2. Physicochemical properties of semisolid formulations of norﬂoxacin∗
Formulation Apparent
base % Drug content pH viscosity, cPs Flow index Spreadability, s Extudability, g
Carbopol 97.4 ± 2.8 7.2 10 × 106 0.35 25 500
PEG† 93.1 ± 3.7 6.3 30 × 106 0.26 38 520
HPMC 99.7 ± 4.8 5.7 45 × 106 0.37 45 578
Ointment 95.3 ± 4.7 6.1 25 × 106 0.22 35 589
∗Values are average of 3 determinations.
†PEG indicates polyethylene glycol; HPMC, hydroxypropylmethyl cellulose.
Evaluation of transdermal formulations
Drug content
A hundred milligrams of formulation was dissolved in 1% v/v acetic acid, filtered, and the
volume was made to 100 mL with 1% v/v acetic acid. The resultant solution was suitably
diluted with 1% v/v acetic acid and absorbance was measured at 277.6 nm. From this the
drug content was determined using calibration curve for norfloxacin.
pH
Direct measurements were made using a digital pH meter.
Rheological studies
The prepared formulations were evaluated for the following rheological characteristics
(Table 2):
 Apparent viscosity at 2.5 rpm, using a Brookfield synchroelectric viscometer.
 Spreadability, using a spreadability apparatus.8 After applying weight, time in seconds
required to separate the slides was noted. Spreadability of each formulation was reported
in seconds.
 Extrudability,usinganextrudabilityapparatus.9 Aclosedcollapsibletubecontainingfor-
mulation was pressed firmly at the crimped end. When the cap was removed, formulation
extruded until the pressure dissipated. Weight in grams required to extrude a 0.5-cm rib-
bon of the formulation in 10 seconds was determined. The average extrusion pressure in
grams was reported.
In vitro release studies
In vitro release studies were carried out using the classical cylindrical tube (Table 3).10
Semisolid formulation (0.5 g) was taken on the cellophane membrane and tied securely to
oneendofthetube,theotherendwaskeptopentoambientconditions.Thecellwasinverted
and immersed slightly in 100.0 mL of 1% v/v acetic acid in a beaker at 37◦C ± 1◦C, and
stirred at 100 rpm for 8 hours. Samples of 5.0 mL were withdrawn at 1-hour intervals and
assayed spectrophotometrically at 277.6 nm.
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Table 3. In vitro drug release proﬁle of semisolid formula-
tions of norﬂoxacin
Formulation base % Drug release after 8 h∗
Carbopol 75.03 ± 3.31
PEG† 69.74 ± 2.28
HPMC 49.13 ± 2.79
Ointment 43.00 ± 3.79
Silver sulfadiazine 1% cream, USP 71.17 ± 3.33
∗Values are average of 3 determinations.
†PEG indicates polyethylene glycol; HPMC, hydroxypropylmethyl cellulose.
Microbiological studies
The antibacterial activity of various semisolid formulations of norfloxacin against various
strains of aerobic and anaerobic microorganisms was evaluated by the standard cup-plate
method and the inhibition zone diameters were measured with the help of a zone reader
(Table 4). Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Pseudomonas aerug-
inosa (aerobic organisms) and Bacteroides fragilis (anaerobic organism) were used for
testing the antibacterial activity. Nutrient agar medium was used for aerobic bacterial cul-
turesandbloodagarmediumwasusedforBacteroidesfragilis.Theaerobicorganismswere
incubated at a temperature of 37◦C ± 0.2◦C for 24 hours in an incubator under aerobic con-
ditions,whileBacteroidesfragiliscultureswereincubatedunderahydrogen/carbondioxide
atmosphere in an anaerobic jar at 37◦C ± 0.2◦C for 48 hours.11
Burn wound healing property
Animals
Healthy Wistar albino rats weighing between 150 and 180 g were used. Animals were
divided into several groups, each containing 5 animals.
Inﬂicting burn wound
The experiments were carried out per the guidelines of Animal Ethics Committee. The
dorsum of each rat was shaved. Burn wounds were inflicted on overnight-starved animals
Table 4. Antimicrobial activity of norﬂoxacin from topical drug delivery system
Inhibition zone diameter, mm∗
Bacillus Staphylococcus Escherichia Pseudomonas Bacteroides
Formulation base subtilis aereus coli aeruginosa fragilis
Carbopol 48.82 50.82 47.32 45.33 49.33
PEG† 43.72 42.33 41.22 42.32 46.21
HPMC 36.32 33.33 31.21 32.33 35.21
Ointment 32.13 31.33 30.23 30.21 30.11
Silver sulfadiazine 1% cream, USP 45.33 51.22 48.31 44.72 47.12
*Values are average of 3 determinations.
†PEG indicates polyethylene glycol; HPMC, hydroxypropylmethyl cellulose.
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Table 5. Percent burn wound contraction of norﬂoxacin formulations
%W ound contraction
Formulation base Day 4 Day 8 Day 12
Control 27.61 ± 1.33∗ 53.31 ± 1.22∗ 67.03 ± 0.92∗
Carbopol 49.13 ± 1.56∗ 70.00 ± 1.86∗ 83.01 ± 0.73∗
Carbopol† 31.03 ± 1.84∗ 58.13 ± 0.37∗ 70.10 ± 0.92∗
PEG 46.12 ± 1.72∗ 67.23 ± 0.32∗ 78.00 ± 0.67∗
PEG† 30.02 ± 1.30v 56.34 ± 0.24∗ 65.31 ± 0.73∗
HPMC 43.13 ± 1.36∗ 59.76 ± 1.21∗ 69.65 ± 0.87∗
HPMC† 30.10 ± 0.72∗ 48.01 ± 0.29∗ 58.03 ± 0.29∗
Ointment 40.23 ± 1.37∗ 57.00 ± 0.78∗ 62.65 ± 0.13∗
Ointment† 29.01 ± 0.93∗ 57.13 ± 0.29∗ 61.00 ± 0.27∗
Silver sulfadiazine 1% cream, USP 52.00 ± 1.45∗ 71.87 ± 0.98∗ 84.34 ± 0.49∗
∗P < .001 vs control.
†Represent the group treated with base alone.
under pentobarbitone sodium (6 mg/100 g, i.p.) anesthesia. A 2 × 2-cm metal cylinder was
placed on the shaven back of the animals. Melted wax at 80◦Cw as poured into the metal
cylinder and the wax was allowed to solidify. Eight minutes after this, until the wax was
completely solidified, the metal cylinder containing wax adhering to the skin was gently
removed to inflict a distinctly demarked burn wound.12
Assessment of burn wound healing
Norfloxacin semisolid formulations and silver sulfadiazine 1% cream, USP, available on
the market were applied (500 mg each) to the wound inflicted areas of animals every day
from day 1. Animals were observed for wound healing by measuring the wound contraction
(tracing the raw wound area first on a transparent polythene paper and then retraced on
graph paper) up to the 12th day postwounding. The wound contraction was calculated as
percentage of original wound size for each animal of a group (Table 5).12
RESULTS AND DISCUSSION
Thedrugcontentofalltheformulationswasfoundtobeingoodagreementwiththetheoret-
ical value, indicating the stability of the drug in the formulations. pH of all the formulations
was found to be between 5.7 and 7.2, which indicated suitability of the formulations for
application on the skin. Rheological properties (spreadability and extrudability) of the nor-
floxacin semisolid formulations were found to be equivalent to silver sulfadiazine cream
USP.
Norfloxacin formulations containing polyethylene glycol and Carbopol gel base
showed better in vitro release profile and gave larger zones of inhibition in comparison
to creams and ointment base formulations, indicating the better activity of the drug. In
creams, owing to their biphasic nature, partitioning of the drug occurs in 2 phases, resulting
in slower release of drug, while in the case of gels, the drug diffusion occurs through the
aqueous phase and hence they offer a greater drug diffusion and release.13
30MALIPEDDIE TA L
The difference between the mean percent burn wound contraction of the norfloxacin
formulation treated animals as compared to control was found to be statistically significant.
Allthepreparedformulations,includingsilversulfadiazine1%cream,USP,hadstatistically
shown wound healing activity (P = .001) in healthy male Wistar albino rats. Burn wound
healing studies revealed a maximum percent wound healing of 83.01% ± 0.73% with car-
bopol formulations within 12 days, which is in good agreement with the silver sulfadiazine
formulation available on the market, showing 84.34% ± 0.49% of wound healing.
CONCLUSION
The in vitro release characteristics along with the burn wound healing property of prepared
topical formulations of Norfloxacin were quite encouraging and in good agreement with
the silver sulfadiazine 1% cream, USP, available on the market. Among all the semisolid
formulationsprepared,Carbopolgelbasewasfoundtobemostsuitabledermatologicalbase
for norfloxacin in comparison with various other dermatological bases. It also has aesthetic
appeal, which other bases lack, an important aspect from patient compliance and consumer
point of view.
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